Inhibikase Announces David McIntyre as New CFO
Company - People | Apr 14, 2025 | EIN
Inhibikase Therapeutics, a clinical-stage pharmaceutical company, has named David McIntyre as its new Chief Financial Officer, effective April 14, 2025. McIntyre brings more than twenty years of experience in the life sciences sector, having held executive roles in several biotech firms. His background includes a partnership in a multibillion-dollar life sciences venture capital fund and legal expertise in mergers and acquisitions from Baker McKenzie and KPMG. Inhibikase, which specializes in developing Abelson Tyrosine Kinase inhibitors for cardiopulmonary diseases, sees McIntyre's appointment as a strategic move to further its development initiatives, particularly for the IkT-001 prodrug for pulmonary arterial hypertension (PAH). CEO Mark Iwicki expressed excitement about the appointment, underscoring its potential impact on advancing their clinical objectives.
Sectors
- Pharmaceuticals
- Corporate Finance
- Venture Capital
Geography
- United States – Inhibikase Therapeutics is headquartered in Atlanta, Georgia, with additional offices indicating operations primarily in the U.S.
- Australia – David McIntyre's professional credentials include qualifications and legal practice admissions in Australia.
Industry
- Pharmaceuticals – The article revolves around Inhibikase Therapeutics, a company developing pharmaceuticals for cardiopulmonary diseases.
- Corporate Finance – David McIntyre's extensive experience in financial strategy and corporate governance is central to the article.
- Venture Capital – McIntyre's past role as a Partner at a life sciences venture capital fund highlights the relevance of this industry.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. | Target Company | Company | A clinical-stage pharmaceutical company specializing in Abelson Tyrosine Kinase inhibitors for cardiopulmonary diseases. |
| David McIntyre | Chief Financial Officer | Person | Recently appointed CFO of Inhibikase Therapeutics with extensive experience in the life sciences sector. |
| Mark Iwicki | Chief Executive Officer | Person | CEO of Inhibikase Therapeutics, overseeing strategic initiatives for the company. |
| Anthos Therapeutics, Inc. | Previous Employer | Company | One of the companies where McIntyre held an executive position. |
| Apple Tree Partners | Former Employer | Company | McIntyre was a Partner at this venture capital and growth equity fund focusing on life sciences. |
| Baker McKenzie | Legal Advisor/Biography | Company | McIntyre previously practiced as a senior attorney specializing in M&A at this firm. |
| KPMG | Legal Advisor/Biography | Company | Another firm where McIntyre worked as a senior attorney specializing in corporate law. |